NCT00467025View on ClinicalTrials.gov

AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib

PHASE2CompletedINTERVENTIONAL
Enrollment

152

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

April 30, 2010

Study Completion Date

June 30, 2014

Conditions
Advanced Renal Cell Carcinoma
Interventions
DRUG

AMG 386

3 mg/kg or 10mg/kg IV weekly until unacceptable toxicity or disease progression

DRUG

Sorafenib

400 mg PO BID

DRUG

AMG 386 placebo IV

AMG 386 placebo IV

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT00467025 - AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib | Biotech Hunter | Biotech Hunter